Showing 1 – 3 of 3 results.
Curated
Criminal Justice Drug Abuse Treatment Studies (CJ-DATS): Restructuring Risky Relationships-HIV (RRR-HIV), 2005-2008 [United States] (ICPSR 30842)
Released/updated on: 2011-07-13
Geographic coverage: Rhode Island, United States, Connecticut, Kentucky, Delaware
Time period: 2005-01-01--2008-01-01
In recent years, women have had a growing presence in the prison system, largely for drug-related offenses. Few interventions are geared towards reentering female offenders, for whom HIV and drug use are intimately tied to risky relationships and thinking errors surrounding criminal activity and risky behavior. This study aimed to develop a manual-driven intervention for the criminal justice system geared towards female drug abusers, specifically reducing HIV risk behavior. Using focus groups to develop the manual, interventionists were then trained and supervised. The intervention focused on reducing risky behavior through cognitive restructuring and the relationship model. The intervention takes place through a two-group design, one with three community reentry sessions, the other without reentry sessions. Outcomes of the study were to develop a manual for women reentering society, to contribute to the literature on the unique factors affecting women and risky behavior, to expand on the existing knowledge of the issues faced by reentering women, and to offer information about the connection between community-based reentry resources and the criminal justice system.
Curated
Restricted
Neuropsychological and Emotional Deficits as Predictors of Correctional Treatment Response in Maryland, 2003-2005 (ICPSR 20349)
Released/updated on: 2008-03-31
Geographic coverage: United States, Maryland
Time period: 2003-03-01--2005-12-01
The study was designed to elucidate underlying neuropsychological and emotional regulatory mechanisms in variable responses to a cognitive-behavioral therapy (CBT) program among prison inmates. This study tested the hypotheses that performance deficits in executive cognitive function (ECF) tasks and emotional responses will characterize aggressive and disruptive inmates and predict treatment response. All subjects were examined using noninvasive behavioral, psychological, ECF, and hormone tests. The data contain a total of 232 cases. Inmates volunteering to participate in the cognitive-behavioral therapy (CBT) program offered by the Maryland correctional system were recruited from three facilities using a pseudo-random selection procedure during intake into the program. Consenting inmates received an extensive baseline testing battery of several complementary dimensions of higher order neuropsychological functions as well as conditions that influence them: (1) three ECF tasks and one emotional perception task, (2) collection of salivary cortisol during an acute stress task and the Symptom Checklist 90 (SCL-90) taken beforehand, (3) a short general neuropsychological test, (4) three psychological questionnaires, (5) an historical inventory to assess prior drug use and child and family background, and (6) a treatment readiness, responsivity, and gain scale. An events inventory and a success inventory were also administered. Several additional tests were administered repeatedly throughout treatment. A record review was conducted after program completion to ascertain incidents of institutional misconduct as well as treatment performance outcomes. Variables include IQ, demographics, background information, prior drug use, early trauma, psychopathy, aggression, stressful events, success, reactions to provocation, treatment readiness, emotional perception/regulation, executive cognitive performance, cortisol measures, treatment gain, treatment responsivity, treatment completion, Maryland Offender Based State Correctional Information System (OBSCIS) data, institutional infractions, segregations, and several other computed variables.
Curated
Simple Crosstabs
Perception and Memory Experiments Using Drug Names [2010, Canada] (ICPSR 34122)
Released/updated on: 2013-04-30
Geographic coverage: Canada, Ontario, Global
Time period: 2012-03-28--2012-03-29, 2012-07-05--2012-07-06
Drug names that look and sound alike are a leading cause of medication errors (e.g., diazepam and diltiazem, hydroxyzine and hydralazine, Paxil and Taxol, fomepizole and omeprazole, Foradil and Toradol). Observational studies of dispensing in outpatient pharmacies suggest that the rate of wrong drug errors -- the type most likely to be the result of name confusion -- is roughly 0.13 percent. With 3.9 billion prescriptions dispensed in 2009, that translates to 5 million wrong drug errors per year in the United States. The purpose of this overall project was to develop, demonstrate, and disseminate a standard protocol for pre-approval testing of drug names, including a standard battery of psycholinguistic tests and data analytic methods, all with comparison to control names and to refine and demonstrate analytic methods by conducting a series of visual perception, auditory perception, and short term memory experiments using drug names as stimuli. The achievement of this aim will provide both regulators and pharmaceutical manufacturers with a scientifically validated, step-by-step method for testing new drug names for confusability. The data for this collection come from four experiments. In each experiment, participants are tested on their ability to correctly identify drug names under four conditions (see study design). Variables include participant reaction time to identify drug names and the percent participants correctly or incorrectly identified drug names. Study participants include medical doctors, nurse practitioners, pharmacists, and pharmacy technicians. Other variables include participant gender, education degree held, primary language spoken, and employment location.